NDV 3
Alternative Names: NDV-3; NDV-3ALatest Information Update: 02 Oct 2021
At a glance
- Originator LA BioMed; NovaDigm Therapeutics
- Developer National Institute of Allergy and Infectious Diseases; NovaDigm Therapeutics
- Class Antibacterials; Antifungals; Bacterial vaccines; Fungal vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Candidiasis; Staphylococcal infections
- Phase I/II Vulvovaginal candidiasis
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 15 Oct 2019 NovaDigm Therapeutics completes a phase IIa trial for Staphylococcal infections (Prevention) in USA (NCT03455309)
- 09 Oct 2018 National Institute of Allergy and Infectious Diseases completes a phase II trial in Candidiasis (Prevention) in USA (NCT02996448)
- 25 Apr 2018 Updated efficacy and adverse events data from a phase IIa trial in Vulvovaginal candidiasis released by NovaDigm Therapeutics